Phase I Study Combining PembRolIzuMab and Hypofractionated Stereotactic Radiotherapy In Patients With Metastatic Non-small-cell lunG Cancer
Latest Information Update: 18 Dec 2017
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Acronyms PRIMING
- 18 Dec 2017 New trial record